Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma

Phase I results from a study of lapatinib with gemcitabine and cisplatin (GC) in advanced/metastatic bladder cancer.

(2017) Gedske Daugaard et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors

(2015) Johanna C. Bendell et al.   INVESTIGATIONAL NEW DRUGS

Comprehensive molecular characterization of urothelial bladder carcinoma

(2014)   NATURE

PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation

(2013) E Seront et al.   BRITISH JOURNAL OF CANCER

Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study

(2013) Yoo-Joung Ko et al.   LANCET ONCOLOGY

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers

(2012) E. Seront et al.   ANNALS OF ONCOLOGY

PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors

(2012) F. Meric-Bernstam et al.   CLINICAL CANCER RESEARCH

Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma

(2012) Yu-Ning Wong et al.   JOURNAL OF CLINICAL ONCOLOGY

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial

(2012) Andrea Necchi et al.   LANCET ONCOLOGY

A phase II trial of temsirolimus in second-line metastatic urothelial cancer

(2012) H. Gerullis et al.   MEDICAL ONCOLOGY

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity

(2011) J. Bellmunt et al.   ANNALS OF ONCOLOGY

Global cancer statistics

(2011) Ahmedin Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]

(2010) P. Albers et al.   ANNALS OF ONCOLOGY

Phase II Study of Sunitinib in Patients With Metastatic Urothelial Cancer

(2010) David J. Gallagher et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens

(2010) Joaquim Bellmunt et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial

(2010) Przemyslaw Twardowski et al.   UROLOGY

A Robust Immunohistochemical Assay for Detecting PTEN Expression in Human Tumors

(2010) Zaina Sangale et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Phase 2 trial of sorafenib in patients with advanced urothelial cancer

(2009) Robert Dreicer et al.   CANCER

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma

(2009) Christian Wülfing et al.   CANCER

Vinflunine in platinum-pretreated patients with locally advanced or metastatic urothelial carcinoma

(2009) David J. Vaughn et al.   CANCER

Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer

(2009) Margaret A. Knowles et al.   CANCER AND METASTASIS REVIEWS

Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract

(2009) Joaquim Bellmunt et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 2 trial of pemetrexed disodium and gemcitabine in advanced urothelial cancer (E4802)

(2008) Robert Dreicer et al.   CANCER

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS